Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31363723 | 0.72 | KDM4E (0.35) | — | |
| SCHEMBL31363344 | 0.72 | KDM4E (0.35) | — | |
| SCHEMBL4713084 | 0.72 | CYP4F2 (0.33) | — | |
| SCHEMBL20341656 | 0.72 | CA1 (0.39) | DPP4DPP7MAPK1PER2CRY1 | |
| SCHEMBL4713086 | 0.72 | CYP4F2 (0.33) | — | |
| SCHEMBL18611355 | 0.71 | PER2 (0.37) | DPP4DPP7MAPK1PER2CRY1 | |
| SCHEMBL16367135 | 0.70 | KMT2A (0.41) | MAPK1 | |
| SCHEMBL18508455 | 0.69 | JAK2 (0.31) | — | |
| SCHEMBL14310631 | 0.68 | — | — | |
| SCHEMBL16367139 | 0.68 | PIK3CD (0.37) | DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019492-B1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-9126982-B2 | Heterocyclic compounds, medicaments containing them, use and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9126982-B2 | Heterocyclic compounds, medicaments containing them, use and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| WO-2015003958-A1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-8536172-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536172-B2 | Inhibitors of JNK | ROCHE PALO ALTO LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110034470-A1 | Inhibitors of JNK | GONG LEYI | 2011-02-10 | — | — | US | disclosed |
| US-20110034470-A1 | Inhibitors of JNK | GONG LEYI | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034470-A1 | Inhibitors of JNK | MAPK1, MAP3K6, MAP3K3 | DPP4 2544/4885DPP7 3497/4885MAPK1 1/4885 |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | DPP4 2192/4885DPP7 2485/4885MAPK1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.